• Home
  • Company
    • Management
    • Board of Directors
    • Advisory Board
  • Technology
    • Publications
  • Partnering
    • Product Pipeline
  • News
    • IN THE PRESS: Cloud Pharmaceuticals CSO Shahar Keinan in "The Scientist"
    • Cloud Pharmaceuticals to Present AI-Based Drug Design at Conferences in May
    • Cloud Pharmaceuticals Wins U.S.-China Health Summit
    • Cloud Pharmaceuticals Selected Finalist in U.S.-China Health Summit
    • Cloud Pharmaceuticals forms Drug Design Collaboration with GSK
    • Cloud Pharmaceuticals CEO to Speak at Artificial Intelligence in Drug Development Congress 27-28 September 2017, London, UK
    • Cloud Pharmaceuticals CEO and CSO to Speak at AI Pharma Innovation
    • Cloud Pharmaceuticals CEO to Speak at the AI in Pharma Summit October17, 2017 in Boston.
    • Cloud Pharmaceuticals CEO and CSO to Speak at AI Pharma Innovation
    • Undruggable? Not to Cloud Pharmaceuticals
    • Cloud Pharmaceuticals Announces Design of Active Pro-Drug for Treatment of Crohn's Disease and Ulcerative Colitis
    • Cloud Pharmaceuticals COO to Discuss Digital Tools for Drug Discovery and Development at the 2016 BIO International Convention
    • Cloud Pharmaceuticals Appoints Neurological Disorder Expert Jeff Vaught to Its Advisory Board
    • Cloud Pharmaceuticals Strengthens Management Team with Appointment of Two C-Level Executives
  • Events
  • Contact
Cloud Pharmaceuticals
Connect with us:

News

Follow @CloudPharm
Cloud Pharmaceuticals Forms Drug Design Collaboration with GSK 

Cloud will use its Artificial Intelligence-driven process to design novel molecules 

Research Triangle Park, NC, May 30, 2018
Cloud Pharmaceuticals, Inc., an Artificial Intelligence-driven drug design and development company, announced today they have entered into drug discovery collaboration with GlaxoSmithKline (GSK). Cloud will design novel small-molecule agents to GSK specified targets. Cloud will use its proprietary AI-driven process to design the molecules.  

Ed Addison, CEO of Cloud Pharmaceuticals, said, "Application of Cloud Pharmaceuticals technology has been proven to dramatically shorten the time from target validation to lead molecule. We believe this agreement validates  the strength of this process and reinforces the value we can offer accelerate the discovery of novel, high-quality drug candidates.”

Don Van Dyke, COO of Cloud and their lead in this collaboration added, “It is estimated that the traditional discovery process to arrive at a clinical candidate molecule takes greater than 5 years. Cloud has consistently been able to reduce that to a matter of a few months.”

Cloud Pharmaceuticals has designed active molecules with academic and commercial partners against a broad variety of drug targets and has published several papers to document its success. Cloud’s proprietary AI-driven process delivers completely novel molecules that have been tailored to the unique characteristics of each drug target.
About Cloud Pharmaceuticals, Inc.

Cloud Pharmaceuticals is committed to improving health and well-being through the computational design and rapid development of new therapies. Its proprietary Quantum Molecular Design process combines artificial intelligence (AI) and cloud computing to search virtual molecular space and applies along sophisticated molecular modeling to design novel drugs. The process enables faster drug development progress at lower cost and a higher success rate and better targeting of hard-to-drug indications. The company partners at all stages of drug development – from discovery through the clinic – and is building an extensive product pipeline that spans a wide range of indications.
###
HOME | COMPANY | TECHNOLOGY | PARTNERING | NEWS | EVENTS | CONTACT

CONTACT US:

Cloud Pharmaceuticals, Inc.

Office: 800 Park Offices Dr., RTP, NC 27709
Mail: PO Box 110081, RTP, NC 27709
Phone: 1.910.398.1200
e-mail: info@cloudpharmaceuticals.com
CONNECT WITH US:


SUBSCRIBE:

Join our contact list to receive news and announcements in your inbox:

Join Now
© 2014 - 2019 Cloud Pharmaceuticals, Inc. | Terms and Conditions of access to www.cloudpharmaceuticals.com